# Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors

> **NCT03891706** · PHASE1 · RECRUITING · sponsor: **Guangzhou FineImmune Biotechnology Co., LTD.** · enrollment: 30 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** tumor-specific TCR-T cells
- **DRUG:** Interleukin-2

## Key facts

- **NCT ID:** NCT03891706
- **Lead sponsor:** Guangzhou FineImmune Biotechnology Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-01-08
- **Primary completion:** 2025-10-01
- **Final completion:** 2025-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03891706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03891706, "Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03891706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*